Expression Of FTO Gene In Breast Cancer Tissues And The Variation In Neoadjuvant Chemotherapy

Background Breast cancer is the common female malignant tumor. Though virous kinds of technology have made great progress in diagnosis and treatment of breast cancer, its treatment effect is far from satisfactory. Neoadjuvant chemotherapy of breast cancer is a new kind of systemic therapy in recent years. Recent studies have demonstrated that it plays a important role in decreasing Tumor staging, increasing the rate of breast-conserving surgery, reducing the micro-metastases and improving the rate pathological response, and it creates conditions and provides guidance for subsequent treatment of breast cancer. Some researches have found that the neoadjuvant chemotherapy can change the expression of some tumor markers and gene. According to some experts’study, obesity can increase the risk of developing breast cancer, while losing weight or certain deeline may reduce the morbidity. The case-control study showed that fetal women’s risk of breast cancer will be increased by three times, and prospective studies showed that obesity seriously affected the median survival an d relapse-free survival of the advanced breast cancer in situ. The developments of bre ast cancer is caused by different carcinogenic factors activating proto-oncogene and inhib iting tumor suppressor genes which lead to cell proliferation and apoptosis disorders t hrough different ways. It has been discovered in recent years that fat and obesity related (FTO) is associated with obesity genes, which is widely expressed in fetal and adult tissues, especially in the hypothalamus, pituitary, adrenal gland and pancreas. Recent research shows that the FTO gene has high expression in prostate cancer, and it has certain relationship with the development of endometrial cancer and pancreatic cancer. The correlations of FTO mRNA expression with formation and development of breast cancer and the variation of its expression in neoadjuvant chemotherapy have not been reported at home and abroad.Objective This study aims to apply reverse transcription polymerase chain reaction technique testing the expression level of normal breast tissue, breast cancer tissue and and the variation in neoadjuvant chemotherapy,in order to discusse the expression of FTO gene in breast cancer tissue and the variation in neoadjuvant chemotherapy. Further explore the relationship between the expression of FTO gene with lymph node metastasis status, ER, PR, HER-2and BMI.Methods28cases of Hyperplasia of mammary glands,24cases of primary breast cancer, and10cases breast cancer who receive neoadjuvant chemotherapy with the chemotherapy regimens of ET (epirubicin80mg/m2, the first day;docetaxel60mg/m2, the first day,3weeks for a cycle.for two to three treatment cycle.) are taken to the group. All cases had operative treatment and the tissue samples were freeze-stored in a refrigerators under80ti within15min after the backup. Frozen breast cancer tissues were cut by scissors weighing right amount and fully grinded in liquid nitrogen.tissue RNA were extracted by RNA kit,and then RNA concentration detected by K5600. Through RT-PCR reaction, the reaction product which was mixed with the sample buffer was cataphoresised in agarose gel and photographed by FluorChem E.The pictures were input Alpha VIEW SA system, The expression level of FTOmRNA and p-actin were the ratio of the size and brightness of of the stripe.The date were divided into two groups according to before and after NAC,if there are lymph node metastasis or not,obesity or not,ER,PR,HER-2negative and postive.The date was statistical analysed by SPSS17.0.Results (1) The expression of FTO was observed in both cyclomastopathy tissue and breast cancer tissue. The expression level in breast cancer was significantly higher than that in cyclomastopathy.(2) The expression of FTO in breast cancer tissue after neoadjuvant chemotherapy was lower than before.(3) The expression level of FTOmRNA in lymphatic metastasic group was higher than none lymphatic metastasic group, but there is no difference between obese and non-obese group. Conclusion Expression of FTO plays an important role in the formation and development of breast cancer;Neoadjuvant chemotherapy can reduce the expression of FTO in breast cancer tissue.The carcinogenic role of FTO gene is not the efifect it causes obesity.